Applying Scientific Criteria to Therapeutic Interchange: A Balanced Analysis of Low-Molecular-Weight Heparins

Ringold DJ, Santell JP, Schneider PJ, Arenberg S. ASHP national survey of pharmacy practice in acute care settings: prescribing and transcribing-1998. American Society of Health-System Pharmacists. Am J Health Syst Pharm 1999;56(2):142–157. American Society of Hospital Pharmacists. ASHP statement on the formulary system. Am J Hosp Pharm 1986;43:2839–2841. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001:119(1) (suppl). American College of Clinical Pharmacy. Position Statement on the Guidelines for Therapeutic Interchange. Pharmacotherapy 1993;13(3):252–256. Managed care pharmacy factsheet-therapeutic substitution. Alexandria, VA; Academy of Managed Care Pharmacy 1996. American Medical Association. Policy H-125.991 Drug Formularies and Therapeutic Interchange, 2000. www.ama-assn.org Therapeutic substitution and formulary systems. American College of Physicians. Ann Intern Med 1990;113(2):160–163. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/ IIIa Inhibitor for Stenting. Lancet 1999;354(9195): 2019–2024. Monrad ES. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 2000;85(8A):2C–9C. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-QWave Coronary Events Study Group. N Engl J Med 1997;337(7):447–452. Hilleman DE, Wurdeman RL, Lenz TL. Therapeutic change of HMG-CoA Reductase Inhibitors in patients with coronary artery disease. Pharmacotherapy 2001;21(4):410–415. Nelson WW, Vermeulen LC, Geurkink EA, Ehlert DA, Reichelderfer M. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med 2000;160(16):2491–2496. Mamdani MM, Reisig CJ, Stevenson JG. Cost analysis of therapeutic interchange of calcium channel blockers for the treatment of hypertension: unexpected results from a conversion program. J Managed Care Pharm 2000;6:390–394. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecularweight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160(2):181–188. Nightingale SL. From the Food and Drug Administration. JAMA 1993;270(14):1672. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecularweight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(5 Suppl):489S–510S. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34(3):890–911. Bollinger KA, Vermeulen LC, Davis SN, Geurkink EA. Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange. Am J Health Syst Pharm 2000;57(4):368–372. Fareed J, Fu K, Yang LH, Hoppensteadt DA. Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost 1999;25 Suppl 3: 51–55. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36(1):110–114. Kaiser B, Kirchmaier CM, Breddin HK, Fu K, Fareed J. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo-studies of venous and arterial thrombosis. Semin Thromb Hemost 1999;25 Suppl 3:35–42. Colwell CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932–940. Leclerc JR, Geerts, WH, Desjardins L, et al. Prevention of VTE after knee arthroplasty: a randomized double-blind trial comparing enoxaparin with warfarin.Ann Inter Med 1996;124:619–626. Spiro TE, Fitzgerald RH, Trowbridge AA, et al. Enoxaparin a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery (abstract). J Bone Joint Surg Br 1995;77(suppl III):317. Planes A, Samama MM, Lensing AW, et al. Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81(1):22–25. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341(11):793–800. Geerts WH, Jay RM, Code KL, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thrombosis after major trauma. N Engl J Med 1996;335:701–707. Harenberg J, Schomaker U, Flosbach CW, et al. Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical patients at increased thromboembolic risk (abstract). Blood 1999;94(suppl 1):399a. Hillbron M, Erilä T, Sotaniemi CW, et al. Comparison of the efficacy and safety of the low-molecular weight heparin enoxaparin with unfractionated heparin in the prevention of deep venous thrombosis in patients with acute ischemic stroke (abstract). Blood 1999;94(suppl 1):183a. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of VTE after elective neurosurgery. N Engl J Med 1998;339:80–85. Hull RD, Pineo GF, Francis C, et al. Low-molecularweight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000;160(14):2199–2207. Levine M, Gent M, Hirsh J, et al. A comparison of lowmolecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334(11):677–681. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72(2):186–190. Hull RD, Raskob GE, Brant RF, et al. Low-molecularweight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000;160(2):229–236. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337(10):663–669. Goldhaber SZ. Optimizing anticoagulant therapy in the management of pulmonary embolism. Semin Thromb Hemost 1999;25 Suppl 3:129–133. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000;83(2):209–211. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(1 Suppl): 132S–175S. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(1 Suppl): 64S–94S. Merli G, Spiro TE, Olsson C, et al. Subcutaneous enoxaparin once or twice daily compared to intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134: 191–202. Partsch T, Kechavarz B, Mostbeck A, et al. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with onceor twice-daily low-molecular-weight heparin. J of Vasc Surg 1996;24(5):775–782. Klein W, Buchwald A, Hillis WS, et al. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. Am J Cardiol 1997;80(5A):30E–34E. Pharmacia & Upjohn. Fragmin (dalteparin sodium injection) Full Prescribing Information, 2000. Turpie AG. Can we differentiate the low-molecularweight heparins? Clin Cardiol 2000;23 Suppl 1(14): I4–I7. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100(15): 1593–1601. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000;36(3): 693–698. Hull RD, Pineo GF, Francis C, et al. Low-molecularweight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000;160(14): 2208–2215. Nilsson PE, Bergqvist D, Benoni G, et al. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin. Orthopedics 1997; 20 Suppl:22–25. O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159(19):2298–2304. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med 1997;157(3): 289–294. Bick RL. Low molecular weight heparins in the outpatient management of venous thromboembolism. Semin Thromb Hemost 1999;25 Suppl 3:97–99. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999;130(10):789–799. O'Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000;139(3):423–429. Rodger M, Bredeson C, Wells P, Beck J, Kearns B, Huebsch L. Cost-effectiveness of low-molecularweight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 1998; 159(8):931–938. Burnakis TG, Bussey HL, Hawkins DW, et al. Therapeutic Interchange of low-molecular-weight heparins. (Letter) Am J Health Syst Pharm 2000; 57:1797–1801. Rhone-Poulenc Rorer Pharmaceuticals Inc. Lovenox (enoxaparin sodium injection) Full Prescribing Information. 2000. Clagett GP, Anderson FA, Jr., Geerts W, Heit JA, et al. Prevention of venous thromboembolism. Chest 1998;114(5 Suppl): 531S–560S. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996;347(9001):561–568. Frisc II Investigators. Long term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 1999;354:701–707. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery-a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67(4): 417–423.